Inhibition of γ-secretase induces G2/M arrest and triggers apoptosis in renal cell carcinoma

Oncology Letters

Volumn 8, Issue 1, 2014, Pages 55-61

  Wu, Kerong ^a   Zhang, Li ^b   Lin, Yiwei ^c   Yang, Kai ^c   Cheng, Yue ^a  

^a NINGBO UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle arrest; Notch; secretase

Indexed keywords

3 (4, 5 DIMETHYL 2 THIAZOLYL) 2, 5 DIPHENYLTETRAZOLIUM BROMIDE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; JAGGED1; N [N (3,5 DIFLUOROPHENACETYL) L ALANYL] S PHENYLGLYCINE T BUTYL ESTER; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER RECURRENCE; CELL PROLIFERATION; CELL VIABILITY ASSAY; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; STAINING; TUMOR VOLUME; VERY ELDERLY; WESTERN BLOTTING;

EID: 84901199811     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2078     Document Type: Article

References (27)

1. Zbar B, Klausner R and Linehan WM: Studying cancer families to identify kidney cancer genes. Annu Rev Med 54: 217-233, 2003.
2. Ljungberg B, Hanbury DC, Kuczyk MA, et al: Renal cell carcinoma guideline. Eur Urol 51: 1502-1510, 2007.
3. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007.
4. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
5. Kim WY and Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004, 2004.
6. Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 284: 770-776, 1999.
7. Bettenhausen B, Hrabě de Angelis M, Simon D, Guenet JL and Gossler A: Transient and restricted expression during mouse embryogenesis of Dll1, a murine gene closely related to Drosophila Delta. Development 121: 2407-2418, 1995.
8. Ellisen LW, Bird J, West DC, et al: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-661, 1991.
9. Miele L, Golde T and Osborne B: Notch signaling in cancer. Curr Mol Med 6: 905-918, 2006.
10. Qi R, An H, Yu Y, et al: Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 63: 8323-8329, 2003.
11. Shi W and Harris AL: Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia 11: 41-52, 2006.
12. Sjölund J, Johansson M, Manna S, et al: Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 118: 217-228, 2008.
13. Ai Q, Ma X, Huang Q, et al: High-level expression of Notch1 increased the risk of metastasis in T1 stage clear cell renal cell carcinoma. PLoS One 7: e35022, 2012.
14. Sun S, Du R, Gao J, et al: Expression and clinical significance of Notch receptors in human renal cell carcinoma. Pathology 41: 335-341, 2009.
15. Wu K, Xu L, Zhang L, Lin Z and Hou J: High Jagged1 expression predicts poor outcome in clear cell renal cell carcinoma. Jpn J Clin Oncol 41: 411-416, 2010.
16. Massi D, Tarantini F, Franchi A, et al: Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol 19: 246-254, 2006.
17. Weng AP and Aster JC: Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 14: 48-54, 2004.
18. Weng AP, Ferrando AA, Lee W, et al: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271, 2004.
19. Ridgway J, Zhang G, Wu Y, et al: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083-1087, 2006.
20. Zeng Q, Li S, Chepeha DB, et al: Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8: 13-23, 2005.
21. Xu L, Zhu Y, Xu J, et al: Notch1 activation promotes renal cell carcinoma growth via PI3K/Akt signaling. Cancer Sci 103: 1253-1258, 2012.
22. Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ and Li H: Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. Proc Natl Acad Sci USA 103: 6889-6894, 2006.
23. Wei P, Walls M, Qiu M, et al: Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 9: 1618-1628, 2010.
24. Rasul S, Balasubramanian R, Filipović A, Slade MJ, Yagüe E and Coombes RC: Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer 100: 1879-1888, 2009.
25. Park SJ, Lee JL, Park I, et al: Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy 58: 468-474, 2012.
26. Banks RE, Tirukonda P, Taylor C, et al: Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66: 2000-2011, 2006.
27. Yao M, Yoshida M, Kishida T, et al: VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94: 1569-1575, 2002.